Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...

A new study has found a way to treat patients with triple-negative breast cancer using a shorter and less toxic treatment plan while achieving similar results to the current standard. The study, ...

Author and wellness advocate Liana Werner-Gray talked about her life-threatening cancer diagnosis and the unconventional treatment path that inspired her to write her book "The Earth Diet." ...

OS Therapies Incorporated (NYSE: OSTX) announced it had entered into an Asset Purchase Agreement with Ayala Pharmaceuticals, Inc. Under this agreement, OS Therapies will acquire all HER2 and Listeria ...

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...

Data presented at the ASCO Gastrointestinal Cancers Symposium showed the regimen may be a new option, but it comes with more treatment and financial toxicity.

Kazia Therapeutics is at the forefront of developing cutting-edge cancer therapies, with a key focus on brain cancer and aggressive tumor types like triple-negative breast cancer. The company’s ...

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, according to a global phase 3 trial.

The Mike Slive Foundation has named the recipients of six prostate cancer research grants. The grants are aimed at continuing the foundation’s stated mission ...

T-cells from the liver and lymph nodes show promising potential for future treatments of liver cancer, according to a new ...

About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.